BD Q2 Interventional Confirms the Surgical Consumables Layer

Becton Dickinson reported fiscal Q2 2026 results on May 7 with the BD Interventional segment generating $1.357 billion in revenue, up 7.3% reported and 5.3% on a foreign-currency-neutral basis, and broad strength across Surgery, Urology and Critical Care, and Peripheral Intervention. The result lands in the same week that Intuitive Surgical lifted full-year 2026 da Vinci procedure growth guidance to 13.5% to 15.5% on Q1 strength, that CMR Surgical continues the U.S. Versius Plus rollout following the December 2025 cholecystectomy clearance, and that Restore Robotics now holds FDA 510(k) clearance for four remanufactured da Vinci instruments. Read across the four developments, the surgical robotics platform competition is at the capital-sale layer, and the durable economic engine for the broader interventional and surgical device market sits in the recurring instrument and consumable layer that BD just confirmed is healthy across an entire focused MedSurg-Interventional portfolio.

BD Q2 Interventional Posts 7.3% Reported Growth Across All Three Sub-Segments

BD reported fiscal Q2 2026 (quarter ended March 31, 2026) on May 7 with continuing-operations revenue of $4.714 billion, up 5.2% reported and 2.6% FXN. The BD Interventional segment generated $1.357 billion at 7.3% reported and 5.3% FXN growth, with broad mid-single-digit performance across the three sub-segments. Peripheral Intervention delivered $515 million at 7.1% reported and 4.0% FXN growth. Urology and Critical Care delivered $430 million at 7.5% reported and 6.5% FXN growth. Surgery delivered $411 million at 7.4% reported and 5.5% FXN growth. CEO Tom Polen described execution as broad-based, with more than 90% of the business delivering mid-single-digit growth, and BD raised its full-year fiscal 2026 adjusted diluted EPS guidance to $12.52 to $12.72 from the prior $12.35 to $12.65 range while reaffirming the revenue growth outlook.

The Q2 results follow the February 9, 2026 completion of BD’s separation of the Biosciences and Diagnostic Solutions business through combination with Waters Corporation, and the continuing-operations BD that posted the 7.3% Interventional growth is now a more focused MedSurg-Interventional company. The Q2 numbers are the first clean quarterly read on the residual portfolio after the spin. Recent product launches feeding the Interventional growth line include the BD CentroVena One central venous catheter insertion system, the BD Pyxis Pro automated dispensing solution in Europe, the Revello vascular covered stent (CE marked), and the Liverty TIPS stent graft (CE marked). The portfolio is built around recurring access, consumable, and instrument products that run against an installed clinical environment, and the residual MedSurg-Interventional profile is the one that surgical robotics and interventional founders should be reading for the durable demand picture in 2026.

Intuitive Surgical Lifts 2026 da Vinci Procedure Growth Guidance to 13.5%-15.5%

Intuitive Surgical reported Q1 2026 on April 22 with revenue of $2.77 billion, up 23% year over year, and net income of $822 million. Da Vinci procedures grew approximately 16% globally, with U.S. procedures up 14% and international procedures up 19%. The company placed 431 da Vinci systems in Q1 versus 367 a year earlier, and 232 of the Q1 placements were da Vinci 5 systems against 147 in the prior-year quarter. CEO Dave Rosa attributed the momentum to a 31% rise in after-hours procedures and higher overall utilization, with general surgery and newer procedures including appendectomy driving the U.S. growth. Intuitive lifted its 2026 worldwide da Vinci procedure growth guidance to 13.5% to 15.5% from the prior 13% to 15% range, and improved the non-GAAP gross profit margin guidance to 67.5% to 68.5%. The da Vinci installed base reached 11,395 systems as of March 31, up 12% year over year.

The structural read is that the Q1 procedure growth across the 11,395-system installed base translates into a recurring instrument and accessory revenue base that delivered roughly 60% of Intuitive’s revenue in 2026, with capital sales contributing about 23% and services contributing the balance. The capital-sale layer where Medtronic Hugo, J&J Ottava, and CMR Versius Plus are now competing produces a fraction of the downstream economic flow that the cleared platforms generate over their installed lives. For the founders building component, instrument, and software platforms that fit into the cleared system architectures, the Intuitive recurring-revenue profile is the operating template for what durable medtech economics look like at scale.

CMR Surgical Versius Plus Continues the Limited US Rollout

CMR Surgical received FDA clearance for the Versius Plus second-generation soft-tissue robotic platform in December 2025 for cholecystectomy, with additional 510(k) submissions pending across general surgery, gynecology, urology, and gastrointestinal procedures. The company introduced the cleared platform to U.S. surgeons at the SAGES 2026 conference in Tampa in late March, and CEO Massimiliano Colella has described the U.S. debut as a watershed moment that follows more than 45,000 procedures conducted globally with the Versius platforms across 30-plus countries. The U.S. soft launch is concentrated on selective hospital and ambulatory surgery center partnerships during 2026, with broader expansion contingent on the additional indication clearances landing through the second half of the year.

The Versius Plus rollout, the J&J Ottava De Novo filing on the FORTE pivotal package presented at ASMBS on May 5, and the Medtronic Hugo measured U.S. expansion together produce three credible cleared or near-cleared challengers to the da Vinci platform on the soft-tissue side. The competitive dynamic at the capital-sale layer is now the most active it has been in two decades. The instrument and consumable layer underneath each cleared platform is where the durable margin sits, and the founders building component, instrument, and software platforms that fit into the cleared system architectures are the ones positioned for the second-half 2026 strategic conversation.

Restore Robotics Expands the da Vinci Instrument Remanufacturing Footprint

Restore Robotics received FDA 510(k) clearance in early April for two additional da Vinci Xi instruments, the permanent cautery hook and the permanent cautery spatula, bringing the total cleared remanufactured da Vinci instrument portfolio to four products. The clearance expands the cost-savings alternative the company offers to hospitals running da Vinci Xi systems, and the structural pressure on the Intuitive instrument-replacement revenue model has measurable margin implications across the installed base over time. Intuitive’s installed base continues to absorb the remanufacturing competition, and the company has continued to outperform Wall Street’s forecasts on the recurring-revenue line through Q1 2026.

The Restore Robotics expansion is a structural reminder that the recurring-instrument layer is not a uncontested margin pool. Founders engineering the recurring-revenue economics into a cleared system architecture have to design for the remanufacturing pressure that will eventually arrive against any commercially successful instrument portfolio, with the design-for-controlled-reuse and supply-chain-control levers built into the architecture from initial product design. The platforms that build the recurring-revenue layer with that structural foresight protect the margin against the remanufacturing competition that the Restore Robotics clearance preview makes inevitable.

What the Numbers Tell Surgical Robotics and Interventional Founders

The four developments together describe a market where the surgical robotics platform competition concentrates at the capital-sale layer, and the durable economics for interventional and surgical device founders sit in the consumable, instrument, and recurring-revenue layer that BD’s 7.3% Interventional growth just confirmed is healthy across the entire MedSurg-Interventional portfolio. Founders building component or instrument platforms that fit into the cleared surgical robotic system architectures, founders building peripheral interventional, urology, and surgical instrument products in adjacencies BD just delivered mid-single-digit growth across, and founders thinking about the strategic conversation in the second half of 2026 should weight their commercial planning toward the recurring-revenue layer rather than the system sale. The valuation conversations for platforms that arrive at the strategic discussion with a credible recurring-revenue economic model run on different multiples than the conversations for platforms whose economic story rests on capital placement.